Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease (Articolo in rivista) (literal)

Anno

• 2011-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

• 10.1016/j.pharmthera.2011.07.004 (literal)

Alternative label

• Armentero, Marie Therese; Pinna, Annalisa; Ferre, Sergi; Luis Lanciego, Jose; Mueller, Christa E.; Franco, Rafael (2011)
  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease
  in Pharmacology & therapeutics (Oxf.)
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Armentero, Marie Therese; Pinna, Annalisa; Ferre, Sergi; Luis Lanciego, Jose; Mueller, Christa E.; Franco, Rafael (literal)

Pagina inizio

• 280 (literal)

Pagina fine

• 299 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 132 (literal)

Rivista

• Pharmacology & therapeutics (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali

• 20 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

• 3 (literal)

Note

• ISI Web of Science (WoS) (literal)
• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• University of Barcelona; IRCCS Natl Inst Neurol C Mondino; CNR Inst Neurosci; National Institute on Aging (NIA); University of Navarra; University of Bonn (literal)

Titolo

• Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease (literal)

Abstract

• Several selective antagonists for adenosine A(2A) receptors (A(2A)R) are currently under evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market. The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D-2 and adenosine A(2A) receptors in the basal ganglia. At present it is believed that A(2A)R antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson's patients. However, a considerable body of data indicates that in addition to ameliorating motor symptoms, adenosine A(2A)R antagonists may also prevent neurodegeneration. Despite these promising indications, one further issue must be considered in order to develop fully optimized antiparkinsonian drug therapy, namely the existence of (hetero)dimers/oligomers of G protein-coupled receptors, a topic that is currently the focus of intense debate within the scientific community. Dopamine D-2 receptors (D(2)Rs) expressed in the striatum are known to form heteromers with A(2A) adenosine receptors. Thus, the development of heteromer-specific A(2A) receptor antagonists represents a promising strategy for the identification of more selective and safer drugs. (C) 2011 Elsevier Inc. All rights reserved. (literal)

Prodotto di

• Istituto di neuroscienze (IN) (Istituto)

Autore CNR

• ANNALISA PINNA (Unità di personale interno)

Insieme di parole chiave

• Parole chiave di "Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease" (Insieme di parole chiave)

Incoming links:

Autore CNR di

• ANNALISA PINNA (Unità di personale interno)

Prodotto

• Istituto di neuroscienze (IN) (Istituto)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Pharmacology & therapeutics (Rivista)

Insieme di parole chiave di

• Parole chiave di "Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease" (Insieme di parole chiave)